The next-generation cancer diagnostics market is expected to grow at a CAGR of 16.5% in the first half of the forecast period and CAGR of 19.1% in the second half of the forecast period. The market is estimated at $1.9bn in 2016 and $4.1bn in 2021.
While the number of new cancer cases is expected to reach 24 million by 2035, the cost savings that could be achieved with early diagnosis will be the main driver for the market. Advances in molecular biology will also help expand the cancer diagnostics test menu.
Companion cancer diagnostics can be costly but we expect them to be increasingly adopted, particularly when choosing expensive cancer therapies. Laboratory automation, standardised commercial cancer tests and affordable benchtop instruments will continue to reduce the costs of molecular testing.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 166-page report you will receive 87 charts – all unavailable elsewhere.
The 166-page report provides clear detailed insight into the next-generation cancer diagnostics market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope
• Forecasts and analysis of the next-generation cancer diagnostics market from 2017 to 2027.
• 5 next-generation cancer diagnostics submarkets forecast and analysis from 2017 to 2027:
– Advanced PCR Techniques
– In Situ Hybridization (ISH)
– Circulating Tumour Cells (CTCs) Analysis
– Microarray
– Next-Generation Sequencing (NGS)
• Revenue forecasts for 8 leading national or regional next-generation cancer diagnostics market from 2017 to 2027:
– US
– EU5
– Japan
– China
– India
– Brazil
– Russia
– Rest of the World
• Assessment of selected leading companies marketing next-generation cancer diagnostics, examining recent performance and outlooks:
– Roche Diagnostics
– Abbott Laboratories
– Qiagen
– Thermo Fisher Scientific
– Agilent Technologies
– Hologic
– Illumina
– Myriad Genetics
• SWOT analysis of the next-generation cancer diagnostics market, and discusses some current trends.
Visiongain’s study is intended for anyone requiring commercial analyses for the next-generation cancer diagnostics market. You find data, trends and predictions.
Buy our report today Next-Generation Cancer Diagnostics Market Forecast 2017-2027: Next-Generation Sequencing (NGS), Microarray, Circulating Tumour Cells (CTCs) Analysis, In Situ Hybridization (ISH), Advanced PCR Techniques.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Overview of Findings
1.2 Structure of the Report
1.3 Global Next-Generation Cancer Diagnostics Market Segmentation
1.4 Why You Should Read This Report
1.5 How This Report Delivers
1.6 Key Questions Answered by This Analytical Report
1.7 Who is This Report For?
1.8 Methodology
1.9 Frequently Asked Questions (FAQ)
1.10 Associated Visiongain Reports
1.11 About Visiongain
2. Introduction to Next-Generation Cancer Diagnostics
2.1 What Is Cancer?
2.2 Cancer Diagnostics: An Overview
2.2.1 Screening
2.2.2 Diagnosis
2.2.3 Staging
2.3 Cancer Diagnosis Methods
2.3.1 Physical Examination
2.3.2 Imaging Techniques
2.3.3 Histopathological and Cytological Techniques
2.3.4 Immunohistochemistry (IHC) Analysis
2.3.5 Circulating Tumour Cell (CTC) Analysis
2.3.6 Molecular Diagnostics and IVD
2.4 Tests for Inherited and Acquired Genetic Mutations
2.5 Companion Diagnostics (CDx)
2.6 Laboratory Developed Test (LDT)
2.7 Precision Medicine
2.8 Government Regulations
2.8.1 The US Approval and Regulation System
2.8.2 The EU Approval and Regulation System
2.9 Market Definition
3. Next-Generation Cancer Diagnostics: World Market 2016-2027
3.1 The Global Next-Generation Cancer Diagnostics Market: Overview
3.2 The Global Next-Generation Cancer Diagnostics Market Forecast 2016-2027
3.3 How Will Segmental Market Shares Change to 2027?
3.4 Biomarkers and Molecular Diagnostics
3.4.1 Biomarkers and Diagnostic Tests for Breast Cancer
3.4.2 Biomarkers and Diagnostic Tests for Prostate Cancer
3.4.3 Biomarkers and Diagnostic Tests for Colorectal Cancer
3.5 Companion Diagnostics and Collaborations between Two Industries
3.6 LDTs to be Replaced by Approved Tests
3.7 Decentralisation of Diagnostic Tests
3.8 Next-Generation Cancer Diagnostics: Drivers and Restraints 2017-2027
4. Next-Generation Cancer Diagnostics Submarkets 2017-2027
4.1 Advanced PCR Techniques
4.1.1 Advanced PCR Techniques Market Forecast 2016-2027
4.1.2 Leading Products in the Real-Time PCR Market
4.1.3 Leading Products in the Digital PCR Market
4.1.4 Pap Tests Being Replaced by PCR Assays
4.1.5 Advanced PCR-Based Techniques: Drivers and Restraints 2017-2027
4.2 In Situ Hybridization (ISH)
4.2.1 ISH Cancer Diagnostics Market Forecast 2016-2027
4.2.2 Leading Products in the ISH Cancer Diagnostics Market
4.2.3 HER2 Tests for Breast Cancer
4.2.4 ISH Cancer Diagnostics: Drivers and Restraints 2017-2027
4.3 Circulating Tumour Cells (CTCs) Analysis
4.3.1 CTCs Analysis Market Forecast 2016-2027
4.3.2 Leading Product in the CTCs Analysis Market
4.3.3 Epic Sciences and LabCorp to Expand in Asia Markets
4.3.4 CTCs Separation by Ultrasound
4.3.5 CTC Clusters More Likely to Cause Metastasis?
4.3.6 CTCs Analysis: Drivers and Restraints 2017-2027
4.4 Microarray
4.4.1 Microarray Cancer Diagnostics Market Forecast 2016-2027
4.4.2 Leading Products in the Microarray Market
4.4.3 Microarray Cancer Diagnostics: Trends and Developments
4.4.4 Microarray Cancer Diagnostics: Drivers and Restraints 2017-2027
4.5 Next-Generation Sequencing (NGS)
4.5.1 NGS Cancer Diagnostics Market Forecast 2016-2027
4.5.2 Leading Products in the NGS Market
4.5.3 NGS Cancer Diagnostics: Trends and Developments
4.5.4 NGS Cancer Diagnostics: Drivers and Restraints 2017-2027
5. Leading National Markets 2017-2027
5.1 World Next-Generation Cancer Diagnostics Market: Regional Forecast 2017-2027
5.1.1 How Will Regional Market Shares Change to 2027?
5.2 US Next-Generation Cancer Diagnostics Market Forecast 2017-2027
5.2.1 FDA Provides Guidance for Molecular Diagnostic Instruments with Combined Functions
5.2.2 Obama Launched 'Precision Medicine Initiative'
5.3 EU5 Next-Generation Cancer Diagnostics Market Forecast 2017-2027
5.3.1 Germany: Leading Market in the EU
5.3.2 France: Reduction in Healthcare Spending
5.3.3 UK: 100,000 Genomes Project
5.3.4 Spain: Recovering from Financial Crisis
5.3.5 Italy: Decreasing Reimbursement
5.4 Japanese Next-Generation Cancer Diagnostics Market Forecast 2017-2027
5.4.1 Takeda Collaborated with NCC in Genomic Screening Project
5.4.2 Qiagen Partnered Hitachi on PCR and NGS Technologies
5.4.3 Increase Cancer Rates in Fukushima after Nuclear Disaster?
5.5 Chinese Next-Generation Cancer Diagnostics Market Forecast 2017-2027
5.5.1 Illumina Entering the Chinese Market
5.5.2 Epigenomics Colorectal Cancer Test Approved in China
5.5.3 China Offered Free Screenings for Cervical and Breast Cancer
5.6 Indian Next-Generation Cancer Diagnostics Market Forecast 2017-2027
5.6.1 Lack of Genetic Testing Regulation
5.6.2 Cancer Genetics Launched NGS Cancer Panel in India
5.7 Brazilian Next-Generation Cancer Diagnostics Market Forecast 2017-2027
5.8 Russian Next-Generation Cancer Diagnostics Market Forecast 2017-2027
5.8.1 IBM’s Collaboration with Russian Companies to Advance Clinical Decision Making
6. Leading Companies in the Next-Generation Cancer Diagnostics Market 2017
6.1 Roche Diagnostics
6.1.1 Roche Diagnostics: Product Portfolio
6.1.2 Roche Diagnostics: Diagnostics Sales Outlook
6.1.3 Cobas HPV Test Approved in the US in 2014
6.1.4 Roche Diagnostics: Recent M&A Activity
6.1.5 Roche Coming Back to the NGS Business?
6.2 Abbott Laboratories
6.2.1 Abbott: Next-Generation Cancer Diagnostics Product Portfolio
6.2.2 Abbott: Diagnostics Sales Outlook
6.2.3 Abbott Obtained Exclusive License for Bladder Cancer Biomarker FGFR3
6.3 Qiagen
6.3.1 Qiagen: Next-Generation Cancer Diagnostics Product Portfolio 2017
6.3.2 Qiagen: Diagnostics Sales Outlook
6.3.3 HalioDx Created from Qiagen Marseille
6.4 Thermo Fisher Scientific
6.4.1 Thermo Fisher Scientific: Business Segments
6.4.2 Thermo Fisher: Next-Generation Cancer Diagnostics Product Portfolio 2015
6.4.3 Thermo Fisher: Life Sciences Outlook
6.4.4 NGS Oncomine Focus Assay for Oncology Research
6.5 Agilent Technologies
6.5.1 Agilent: Next-Generation Cancer Diagnostics Product Portfolio
6.5.2 Agilent: Life Sciences and Diagnostics Sales Outlook
6.5.3 Partnerships and Collaborations for Companion Diagnostics
6.6 Hologic
6.6.1 Hologic: Next-Generation Cancer Diagnostics Product Portfolio
6.6.2 Hologic: Diagnostics Sales Outlook
6.7 Illumina
6.7.1 Illumina: Technology and Product Portfolio
6.7.2 Illumina: Sales Outlook
6.7.3 Illumina: Recent M&A Activity
6.7.4 Joined Forces with UK Government for 100,000 Genomes Project
6.7.5 Partnered with Merck Serono to Develop NGS Cancer Diagnostics
6.7.6 Investing on Synthetic DNA Manufacturing Technology
6.8 Myriad Genetics
6.8.1 Myriad: Next-Generation Cancer Diagnostics Product Portfolio
6.8.2 Myriad: Sales Outlook
6.8.3 New Landscape in the BRCA Diagnostic Market
7. Qualitative Analysis of the Next-Generation Cancer Diagnostics Market 2017-2027
7.1 SWOT Analysis of the Next-Generation Cancer Diagnostics Market
7.2 Strengths
7.2.1 Global Cancer Rates Set to Soar
7.2.2 Increasing Awareness of Molecular Cancer Diagnostics
7.2.3 The Trend in Precision Medicine
7.3 Weaknesses
7.3.1 Industry Facing Increasing Reimbursement Pressure
7.3.2 Physicians’ Reliance on Traditional Methods
7.4 Opportunities
7.4.1 Expanding Biomarkers and Cancer Test Menus
7.4.2 Emerging Market to Provide Future Growth
7.4.3 Companion Diagnostics on the Rise
7.5 Threats
7.5.1 Decreasing Healthcare Spending
7.5.2 Gene Patenting Banned in the US?
8. Conclusions
8.1 The World Next-Generation Cancer Diagnostics Market
8.1.1 Current Leading Next-Generation Cancer Diagnostics Segments
8.1.2 Notable Next-Generation Cancer Diagnostics Companies
8.1.3 Leading Regional Markets
8.1.4 World Next-Generation Cancer Diagnostics Market Forecast 2017-2027
8.2 The Future of the Next-Generation Cancer Diagnostics Market
Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain report evaluation form
List of Figures
Figure 1.1 New Cancer Cases and Deaths in More Developed and Less Developed Regions
Figure 1.2 Global Next-Generation Cancer Diagnostics Market Segmentation Overview 2017
Figure 3.1 Most Common Causes of Cancer Death, 2012
Figure 3.2 The Next-Generation Cancer Diagnostics Market: Revenue ($m), AGR (%), 2016-2027
Figure 3.3 Market Shares (%) of Leading Next-Generation Cancer Diagnostics Market Segments, 2016
Figure 3.4 Market Shares (%) of Leading Next-Generation Cancer Diagnostics Market Segments, 2021
Figure 3.5 Market Shares (%) of Leading Next-Generation Cancer Diagnostics Market Segments, 2027
Figure 3.6 Next-Generation Cancer Diagnostics: Market Drivers and Restraints 2017-2027
Figure 4.1 Advanced PCR Techniques Market: Revenue ($m), AGR (%), 2016-2027
Figure 4.2 Advanced PCR-Based Techniques: Drivers and Restraints 2017-2027
Figure 4.3 ISH Cancer Diagnostics Market: Revenue ($m), AGR (%), 2016-2027
Figure 4.4 ISH Cancer Diagnostics: Drivers and Restraints 2017-2027
Figure 4.5 CTCs Analysis Market: Revenue ($m), AGR (%), 2016-2027
Figure 4.6 CTCs Analysis: Drivers and Restraints 2017-2027
Figure 4.7 Microarray Cancer Diagnostics Market: Revenue ($m), AGR (%), 2016-2027
Figure 4.8 Microarray Cancer Diagnostics: Drivers and Restraints 2017-2027
Figure 4.9 NGS Cancer Diagnostics Market: Revenue ($m), AGR (%), 2016-2027
Figure 4.10 NGS Cancer Diagnostics: Drivers and Restraints 2017-2027
Figure 5.1 New Cancer Cases and Deaths in More Developed and Less Developed Regions
Figure 5.2 World Next-Generation Cancer Diagnostics Market: Revenues ($m) by Region, 2016-2027
Figure 5.3 World Next-Generation Cancer Diagnostics Market: Market Shares (%) by Regional Market, 2016
Figure 5.4 World Next-Generation Cancer Diagnostics Market: Market Shares (%) by Regional Market, 2021
Figure 5.5 World Next-Generation Cancer Diagnostics Market: Market Shares (%) by Regional Market, 2027
Figure 5.6 US Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2016-2027
Figure 5.7 EU5 Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2016-2027
Figure 5.8 Japanese Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2016-2027
Figure 5.9 Chinese Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2016-2027
Figure 5.10 Indian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2016-2027
Figure 5.11 Brazilian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2016-2027
Figure 5.12 Russian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2016-2027
Figure 6.1 Roche Diagnostics: Revenue Share (%) by Segment, 2016
Figure 6.2 Roche Diagnostics: Diagnostics Revenue ($m), AGR (%), 2011-2016
Figure 6.3 Roche Diagnostics: Net Sales ($bn) by Region, 2016
Figure 6.4 Abbott: Diagnostics Revenue ($m), AGR (%), 2011-2016
Figure 6.5 Qiagen: Molecular Diagnostics Revenue ($m), AGR (%), 2011-2016
Figure 6.6 Life Technologies: Revenue ($m), AGR (%), 2008-2012
Figure 6.7 Agilent: Life Sciences and Diagnostics Revenue ($m), AGR (%), 2011-2016
Figure 6.8 Hologic: Diagnostics Revenue ($m), AGR (%), 2011-2016
Figure 6.9 Illumina: Revenue Share (%) by Business Segment, 2016
Figure 6.10 Illumina: Revenue Share (%) by Geographic Area, 2016
Figure 6.11 Illumina: Revenue ($m), AGR (%), 2011-2016
Figure 6.12 Myriad: Revenue ($m), AGR (%), 2011-2016
List of Tables
Table 1.1 Leading National Next-Generation Cancer Diagnostics Market Forecast 2016-2027 ($m, AGR%, CAGR%)
Table 3.1 The Next-Generation Cancer Diagnostics Market: Revenue ($m), AGR (%), CAGR (%), 2017-2027
Table 3.2 Selected Biomarkers For Cancer Diagnostics
Table 3.3 FDA Approved Nucleic Acid Based Tests
Table 3.4 Selected Molecular Diagnostic Tests for Breast Cancer
Table 3.5 Selected Molecular Diagnostic Tests for Prostate Cancer
Table 3.6 Selected Molecular Diagnostics Test for Colorectal Cancer
Table 3.7 Companion Diagnostic Devices Approved by FDA
Table 4.1 Advanced PCR Techniques Market: Revenue ($m), AGR (%), CAGR (%),
2016-2027
Table 4.2 ISH Cancer Diagnostics Market: Revenue ($m), AGR (%), CAGR (%),
2016-2027
Table 4.3 CTCs Analysis Market: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 4.4 Microarray Cancer Diagnostics Market: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 4.5 NGS Cancer Diagnostics Market: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 5.1 World Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Region, 2017-2027
Table 5.2 US Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 5.3 EU5 Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 5.4 Japanese Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 5.5 Chinese Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 5.6 Indian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 5.7 Brazilian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 5.8 Russian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
Table 6.1 Roche: Overview
Table 6.2 Roche Diagnostics: Key Instrument/Device Launches Planned
Table 6.3 Roche Diagnostics: Key Test Launches
Table 6.4 Roche Diagnostics: Diagnostics Revenue ($m), AGR (%), CAGR (%), 2011-2016
Table 6.5 Abbott Laboratories: Overview
Table 6.6 Abbott: Diagnostics Revenue ($m), AGR (%), CAGR (%), 2011-2016
Table 6.7 Qiagen: Overview
Table 6.8 Qiagen: Molecular Diagnostics Revenue ($m), AGR (%), CAGR (%), 2011-2016
Table 6.9 Thermo Fisher: Overview
Table 6.10 Thermo Fisher: Life Sciences Solutions Segment Revenue ($m), AGR (%), 2012-2015
Table 6.11 Life Technologies: Revenue ($m), AGR (%), CAGR (%), 2008-2012
Table 6.12 Agilent: Overview
Table 6.13 Agilent: Life Sciences and Diagnostics Revenue ($m), AGR (%), CAGR (%), 2011-2016
Table 6.14 Hologic: Overview
Table 6.15 Hologic: Diagnostics Revenue ($m), AGR (%), CAGR (%), 2011-2016
Table 6.16 Illumina: Overview
Table 6.17 Illumina: Sequencing Product Portfolio
Table 6.18 Illumina: Microarray Product Portfolio
Table 6.19 Illumina: Revenue ($m), AGR (%), CAGR (%), 2011-2016
Table 6.20 Myriad: Overview
Table 6.21 Myriad: Revenue ($m), AGR (%), CAGR (%), 2011-2016
Table 7.1 SWOT Analysis of the Next-Generation Cancer Diagnostics Market, 2017-2027
